Pulmonary Fibrosis Treatment Market
Pulmonary Fibrosis Treatment Market Study by Monotherapy, Combination Therapy, and Symptomatic Therapy for Idiopathic Pulmonary Fibrosis and Familial PF from 2024 to 2034
Analysis of Pulmonary Fibrosis Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pulmonary Fibrosis Treatment Market Outlook (2024 to 2034)
The global pulmonary fibrosis treatment market size is analyzed to increase from US$ 3.29 billion in 2024 to US$ 6.07 billion by the end of 2034. Worldwide revenue from pulmonary fibrosis treatment is projected to increase at a CAGR of 6.3% from 2024 to 2034.
The lungs play a crucial role in human survival, and living a healthy life becomes significantly challenging when diseases such as pulmonary fibrosis impair their function, making breathing difficult. Pulmonary fibrosis specifically damages the tissues surrounding the air sacs in the lungs, causing them to scar and stiffen over time, which progressively restricts breathing. In today's era of heightened pollution, more individuals are experiencing respiratory issues and seeking treatments for pulmonary fibrosis, thereby creating expanding opportunities in the market.
- The National Institutes of Health (NIH) estimates that approximately 100,000 Americans suffer from idiopathic pulmonary fibrosis (IPF), with between 30,000 and 40,000 new cases diagnosed annually. Globally, IPF affects between 13 to 20 individuals per 100,000 people.
- According to Respiratory Research, there were 4,278 individuals with IPF in the MDV database, while Japan estimated a total of 34,040 patients (mean age: 73 years, 73% male), equating to a frequency of 27 cases per 100,000 people.
Various factors contribute to the development of IPF, predominantly habits such as smoking, infections, certain medications, acid reflux, and exposure to air pollution. Those living near metropolitan areas often contend with increased pollution from urban traffic, which heightens the risk of developing pulmonary fibrosis and drives growth in treatments for the condition.
- In 2022, the United States released approximately 66 million tons of pollutants into the atmosphere, as reported by the Environmental Protection Agency. These emissions contribute significantly to respiratory illnesses, acid rain, ozone and particle production, and visibility impairment.
- According to the World Health Organization (WHO), nine out of ten people breathe air that exceeds WHO guideline limits for contaminants. Individuals with interstitial lung disease (ILD), including pulmonary fibrosis (PF), are particularly vulnerable to the harmful effects of environmental pollution, which may increase the likelihood of developing PF.
In response to the rising incidence of pulmonary fibrosis, various medical therapies have been introduced, including monotherapy, combination therapy, and symptomatic treatments. As urban populations continue to grow, prevalence of pollution-related health issues is projected to rise, presenting opportunities for stakeholders in the pulmonary fibrosis treatment market.
| Report Attribute | Detail |
|---|---|
| Pulmonary Fibrosis Treatment Market Size (2024E) | US$ 3.29 Billion |
| Forecasted Market Value (2034F) | US$ 6.07 Billion |
| Global Market Growth Rate (2024 to 2034) | 6.3% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 8.5% CAGR |
| China Market Value (2034F) | US$ 350 Million |
| North America Market Share (2024E) | 71.2% |
| East Asia Market Share (2034F) | 9.5% |
| Key Companies Profiled | F. Hoffman - La Roche Ltd.; Boehringer Ingelheim; International GmbH; Cipla Ltd (Cipla); Gilead Sciences, Inc.; Bristol-Myers Squibb Company; FibroGen Inc.; Galecto, Inc. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How are Pharmaceutical Companies Capitalizing on Opportunities in This Market?
“Investments in Rigorous Clinical Trials and Regulatory Processes to Obtain Approvals”
Pharmaceutical manufacturers focusing on pulmonary fibrosis medications prioritize building robust pipelines and enhancing patient compliance for upcoming launches. Many companies are actively developing new therapies for this condition, including potential biologics expected to undergo assessment and potentially debut in the coming years. To capitalize on the market, these medication producers engage in diverse research initiatives and navigate regional drug approval processes.
- On August 28, 2023, Lupin, a global pharmaceutical company, announced United States FDA approval for a new generic version of Esbriet (pirfenidone) to treat idiopathic pulmonary fibrosis (IPF).
- Boehringer Ingelheim reported on July 25, 2023, that the FDA had accepted their supplemental New Drug Application (sNDA) for OFEV (nintedanib), exploring its potential for treating fibrosing interstitial lung disease (ILD) in children and adolescents aged 6 to 17.
Industry stakeholders invest significant resources in developing innovative solutions. Regulatory bodies like the FDA actively evaluate these advancements, facilitating the approval of new drugs as medical knowledge progresses.
“Incorporation of Artificial Intelligence in Diagnostics”
Recognizing the severity of the disease, medical professionals from various institutions are increasingly dedicating their efforts to researching more effective treatments with minimal side effects. As our understanding of pulmonary fibrosis advances, the potential for developing improved drugs grows, thereby contributing to pulmonary fibrosis treatment market growth.
- Spearheading a nationwide initiative, researchers at the University of Sydney are investigating genetic links to lung disorders and leveraging artificial intelligence (AI) to enhance early detection and treatment.
- On January 16, 2024, the FDA granted de novo clearance to Imvaria, an AI start-up, for a digital diagnostic tool that analyzes chest CT images to detect signs of idiopathic pulmonary fibrosis.
How Does Poor IPF Diagnosis Affect Market Growth?
“Substantial Cost of Treatment and Limited Research Funding”
One of the primary barriers hindering the expansion of the pulmonary fibrosis market size is the challenge of diagnosis. Idiopathic pulmonary fibrosis (IPF) often mimics other lung conditions, making diagnosis difficult. This can lead to poorer prognoses and delays in treatment. Furthermore, market expansion is hindered by limited treatment options and a lack of guaranteed outcomes.
Due to the rarity of IPF, awareness among the general population is low. This lack of awareness can make it difficult for patients to find healthcare providers with expertise in the disease, resulting in delays in diagnosis and treatment. Moreover, the high cost of therapy places a significant financial burden on patients and their families. All these factors collectively impede market growth.
- Pulmonary fibrosis research indicates that delayed diagnosis due to inadequate IPF treatment is prevalent in the United States. A study found that 98% of 45,000 patients were initially misdiagnosed, with 10% receiving anti-fibrotic medications.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Analysis
The market in China is projected to advance at a CAGR of 9.1% from 2024 to 2034. The country is estimated to occupy a pulmonary fibrosis treatment market share of 60.5% in East Asia by the end of 2034.
How are Public and Private Entities Contributing to IPF Treatment in the United States?
“Increasing Public Health Education Campaigns and Significant Research Investments”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 2.31 Billion |
| Growth Rate (2024 to 2034) | 5.8% CAGR |
| Projected Value (2034F) | US$ 4.06 Billion |
The United States is heavily investing in research to understand the mechanisms of pulmonary fibrosis. This includes funding from government agencies like the National Institutes of Health (NIH) and private sector investments aimed at discovering new therapeutic targets and developing novel treatments.
- A recent foundation poll, reported by HealthDay News, found that over 80% of smokers are unfamiliar with pulmonary fibrosis.
This is a concerning statistic for a group disproportionately affected by the disease. Awareness of pulmonary fibrosis is low among both smokers and nonsmokers, with nearly nine out of ten Americans unaware of its symptoms, which include fatigue, shortness of breath, and a persistent dry cough.
What is the Demand Growth Projection for Pulmonary Fibrosis Treatment in South Korea?
“Market Benefitting from Availability of Affordable Skilled Labor for Drug Manufacturing”
| Attribute | South Korea |
|---|---|
| Market Value (2024E) | US$ 12 Million |
| Growth Rate (2024 to 2034) | 10.6% CAGR |
| Projected Value (2034F) | US$ 33 Million |
South Korea has a surplus of skilled labor available at affordable prices, making it highly attractive for outsourcing various projects. Increased funding and budgets, robust R&D efforts, the formation of public and private enterprises, and the attraction of foreign direct investments are key pulmonary fibrosis treatment market trends.
Category-wise Evaluation
Based on distribution channel, the retail pharmacy segment is analyzed to expand at a CAGR of 6.3% from 2024 to 2034.
What are the Primary Benefits of Monotherapy in Treating Pulmonary Fibrosis?
“Fewer Side Effects with Monotherapy and Lower Treatment Cost”
| Attribute | Monotherapy |
|---|---|
| Segment Value (2024E) | US$ 2.38 Billion |
| Growth Rate (2024 to 2034) | 6.3% CAGR |
| Projected Value (2034F) | US$ 4.38 Billion |
Treatment with a single medication at a time is called monotherapy. Pulmonary fibrosis treatment often involves monotherapy using various medications. The three primary options utilized as monotherapy for treating pulmonary fibrosis are pirfenidone, nintedanib, and prednisone (a corticosteroid).
Monotherapy is preferred over other treatment methods due to its advantages, which include fewer side effects, lower costs, better seizure control, and no drug interactions. These benefits drive the market's growth.
Which Indication Accounts for a Substantial Revenue in This Market?
“Idiopathic Pulmonary Fibrosis Holds Significant Share Due to its Progressive Nature”
| Attribute | Idiopathic Pulmonary Fibrosis |
|---|---|
| Segment Value (2024E) | US$ 3.02 Billion |
| Growth Rate (2024 to 2034) | 6.3% CAGR |
| Projected Value (2034F) | US$ 5.56 Billion |
IPF is one of the most common forms of pulmonary fibrosis. Its significant prevalence makes it a major focus for medical research, treatment development, and healthcare resource allocation. There are limited effective treatment options for IPF, which means there is a significant medical need.
- Idiopathic pulmonary fibrosis (IPF) affects up to 207,000 people in the United States alone, according to Lung Org. Additionally, around 55,000 new cases of IPF are diagnosed each year.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Market Landscape
Key players in the pulmonary fibrosis treatment market are engaging in consolidation initiatives, including mergers and acquisitions. A further noteworthy strategy observed in the sector is the growth of business partnerships to enhance pulmonary fibrosis treatment offerings and adapt themselves to the evolving market trends such as cystic fibrosis devices, cutaneous fibrosis treatment, and pulmonary arterial hypertension.
- According to the German News Agency (DPA), a research team based in the United States has created an analytical tool that may help find a treatment for idiopathic pulmonary fibrosis, or IPF, by using a novel method for creating blood vessels from living lung tissue in the lab.
Fact.MR provides detailed information about the price points of key pulmonary fibrosis treatment providers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this latest market report.
Key Segments of Pulmonary Fibrosis Treatment Market Research
-
By Therapy :
- Monotherapy
- Pirfenidone Therapy
- Nintedanib Therapy
- Corticosteroids Therapy
- Combination Therapy
- Pirfenidone & Corticosteroid
- Nintedanib & Corticosteroid
- Pirfenidone & Antitussive
- Others
- Symptomatic Treatment
- Monotherapy
-
By Indication :
- Idiopathic Pulmonary Fibrosis (IPF)
- Familial PF
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Mail Order Pharmacies
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Therapy
- 6.2. Indication
- 6.3. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Therapy
- 7.1. Monotherapy
- 7.2. Combination Therapy
- 7.3. Symptomatic Treatment
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication
- 8.1. Idiopathic Pulmonary Fibrosis (IPF)
- 8.2. Familial PF
- 8.3. Others
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 9.1. Hospital Pharmacies
- 9.2. Retail Pharmacies
- 9.3. Mail Order Pharmacies
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. Middle East & Africa
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 by Therapy, Indication, Distribution Channel, and Region for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. F. Hoffman - La Roche Ltd.
- 20.2. Boehringer Ingelheim
- 20.3. International GmbH
- 20.4. Cipla Ltd (Cipla)
- 20.5. Gilead Sciences, Inc.
- 20.6. Bristol-Myers Squibb Company
- 20.7. FibroGen Inc.
- 20.8. Galecto, Inc.
- 21. Assumptions and Acronyms Used
- 22. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 13: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 14: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 15: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 25: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 26: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 27: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 28: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 29: Latin America Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 30: Latin America Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 37: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 38: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 39: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 40: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 41: Western Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 42: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 43: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 44: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 45: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 49: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 50: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 51: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 52: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 53: Eastern Europe Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 54: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 55: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 56: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 57: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 58: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 65: East Asia Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 66: East Asia Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 67: East Asia Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 68: East Asia Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 69: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 70: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 71: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 72: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 73: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 74: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 75: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 76: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 77: South Asia & Pacific Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 78: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 79: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 80: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 81: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 82: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 83: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 84: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 85: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 86: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 87: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 88: MEA Market Value (US$ Mn) Analysis, by Therapy, 2019 to 2023
Table 89: MEA Market Value (US$ Mn) Analysis, by Therapy, 2024 to 2034
Table 90: MEA Market Value (US$ Mn) Opportunity Analysis, by Therapy, 2024 to 2034
Table 91: MEA Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 92: MEA Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 93: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 94: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 95: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 96: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 17: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 18: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 19: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 20: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 21: North America Market Share Analysis by Country, 2024 & 2034
Figure 22: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 23: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 24: North America Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 33: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 34: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 35: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 36: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 37: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 38: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 39: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 40: Latin America Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 41: Latin America Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 42: Latin America Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 43: Latin America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 49: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 50: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 51: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 52: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 53: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 54: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 55: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 56: Western Europe Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 57: Western Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 58: Western Europe Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 59: Western Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 60: Western Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 61: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 62: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 66: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 67: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 68: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 69: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 70: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 71: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 72: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 73: Eastern Europe Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 74: Eastern Europe Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 75: Eastern Europe Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 76: Eastern Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 77: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 78: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 79: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 80: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 81: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 82: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 83: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 84: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 85: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 86: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 87: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 88: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 89: East Asia Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 90: East Asia Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 91: East Asia Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 92: East Asia Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 93: East Asia Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 94: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 95: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 96: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 97: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 98: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 99: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 100: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 101: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 102: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 103: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 104: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 105: South Asia & Pacific Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 106: South Asia & Pacific Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 107: South Asia & Pacific Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 108: South Asia & Pacific Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 109: South Asia & Pacific Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 110: South Asia & Pacific Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 111: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 112: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 113: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 114: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 115: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 116: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 117: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 118: MEA Market Share Analysis by Country, 2024 & 2034
Figure 119: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 120: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 121: MEA Market Share and BPS Analysis by Therapy, 2024 & 2034
Figure 122: MEA Market Y-o-Y Growth Projections by Therapy, 2024 to 2034
Figure 123: MEA Market Attractiveness Analysis by Therapy, 2024 to 2034
Figure 124: MEA Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 125: MEA Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 126: MEA Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 127: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 128: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 129: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the pulmonary fibrosis treatment market in 2024?
The global market for pulmonary fibrosis treatment is approximated at US$ 3.29 billion in 2024.
How much will the revenue from pulmonary fibrosis treatment therapies be by 2034?
The pulmonary fibrosis treatment market is forecasted to reach US$ 6.07 billion by 2034.
At what rate is the global market forecasted to advance?
Demand for IPF therapies is calculated to increase at a CAGR of 6.3% from 2024 to 2034.
What is the current market value in North America?
The North American market is estimated at US$ 2.34 billion in 2024.
What is the future of the IPF market in South Korea?
The market in South Korea is foreseen to increase at a CAGR of 10.6% through 2034.
What is the projected revenue from monotherapy?
Revenue from monotherapy is forecasted to reach US$ 4.38 billion by 2034.
Who are the leading players in this market?
Top companies in the market are F. Hoffman-La Roche Ltd., Boehringer Ingelheim, and International GmbH.
Which country is a key market in this business?
The United States market is foreseen to advance at a CAGR of 5.8% and reach US$ 4.06 billion by 2034.
Pulmonary Fibrosis Treatment Market